Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma

S. Yamasaki, R. Suzuki, K. Hatano, K. Fukushima, H. Iida, S. Morishima, Y. Suehiro, T. Fukuda, N. Uchida, H. Uchiyama, H. Ikeda, A. Yokota, K. Tsukasaki, H. Yamaguchi, J. Kuroda, H. Nakamae, Y. Adachi, Ken-ichi Matsuoka, Y. Nakamura, Y. Atsuta & 1 others J. Suzumiya

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning remains controversial in patients with relapsed lymphoma. We retrospectively analyzed incidence and risk factors for the development of t-AML/MDS in lymphoma patients treated with autologous or allogeneic HCT. A total of 13 810 lymphoma patients who received autologous (n=9963) or allogeneic (n=3847) HCT between 1985 and 2012 were considered. At a median overall survival (OS) of 52 and 46 months in autologous and allogeneic HCT groups, respectively, lymphoma patients receiving autologous HCT (1.38% at 3 years after autologous HCT) had a significant risk for developing t-AML/MDS compared to allogeneic HCT (0.37% at 3 years after allogeneic HCT, P<0.001). Significant risk factors for the development of t-AML/MDS after autologous and allogeneic HCT were high-stage risk at HCT (P=0.04) or secondary malignancies (P<0.001) and receiving cord blood stem cell (P=0.03) or involved field radiotherapy (P=0.002), respectively. Strategies that carefully select lymphoma patients for autologous HCT, by excluding lymphoma patients with high-stage risk at HCT, may allow the identification of individual lymphoma patients at particular high risk for t-AML/MDS.

Original languageEnglish
Pages (from-to)969-976
Number of pages8
JournalBone Marrow Transplantation
Volume52
Issue number7
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Myelodysplastic Syndromes
Cell Transplantation
Acute Myeloid Leukemia
Lymphoma
Therapeutics
Fetal Blood
Blood Cells
Radiotherapy
Stem Cells

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Yamasaki, S., Suzuki, R., Hatano, K., Fukushima, K., Iida, H., Morishima, S., ... Suzumiya, J. (2017). Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma. Bone Marrow Transplantation, 52(7), 969-976. https://doi.org/10.1038/bmt.2017.52

Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma. / Yamasaki, S.; Suzuki, R.; Hatano, K.; Fukushima, K.; Iida, H.; Morishima, S.; Suehiro, Y.; Fukuda, T.; Uchida, N.; Uchiyama, H.; Ikeda, H.; Yokota, A.; Tsukasaki, K.; Yamaguchi, H.; Kuroda, J.; Nakamae, H.; Adachi, Y.; Matsuoka, Ken-ichi; Nakamura, Y.; Atsuta, Y.; Suzumiya, J.

In: Bone Marrow Transplantation, Vol. 52, No. 7, 01.07.2017, p. 969-976.

Research output: Contribution to journalArticle

Yamasaki, S, Suzuki, R, Hatano, K, Fukushima, K, Iida, H, Morishima, S, Suehiro, Y, Fukuda, T, Uchida, N, Uchiyama, H, Ikeda, H, Yokota, A, Tsukasaki, K, Yamaguchi, H, Kuroda, J, Nakamae, H, Adachi, Y, Matsuoka, K, Nakamura, Y, Atsuta, Y & Suzumiya, J 2017, 'Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma', Bone Marrow Transplantation, vol. 52, no. 7, pp. 969-976. https://doi.org/10.1038/bmt.2017.52
Yamasaki, S. ; Suzuki, R. ; Hatano, K. ; Fukushima, K. ; Iida, H. ; Morishima, S. ; Suehiro, Y. ; Fukuda, T. ; Uchida, N. ; Uchiyama, H. ; Ikeda, H. ; Yokota, A. ; Tsukasaki, K. ; Yamaguchi, H. ; Kuroda, J. ; Nakamae, H. ; Adachi, Y. ; Matsuoka, Ken-ichi ; Nakamura, Y. ; Atsuta, Y. ; Suzumiya, J. / Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma. In: Bone Marrow Transplantation. 2017 ; Vol. 52, No. 7. pp. 969-976.
@article{b9db5ab7660f49a1b95a73bfb171ee52,
title = "Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma",
abstract = "Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning remains controversial in patients with relapsed lymphoma. We retrospectively analyzed incidence and risk factors for the development of t-AML/MDS in lymphoma patients treated with autologous or allogeneic HCT. A total of 13 810 lymphoma patients who received autologous (n=9963) or allogeneic (n=3847) HCT between 1985 and 2012 were considered. At a median overall survival (OS) of 52 and 46 months in autologous and allogeneic HCT groups, respectively, lymphoma patients receiving autologous HCT (1.38{\%} at 3 years after autologous HCT) had a significant risk for developing t-AML/MDS compared to allogeneic HCT (0.37{\%} at 3 years after allogeneic HCT, P<0.001). Significant risk factors for the development of t-AML/MDS after autologous and allogeneic HCT were high-stage risk at HCT (P=0.04) or secondary malignancies (P<0.001) and receiving cord blood stem cell (P=0.03) or involved field radiotherapy (P=0.002), respectively. Strategies that carefully select lymphoma patients for autologous HCT, by excluding lymphoma patients with high-stage risk at HCT, may allow the identification of individual lymphoma patients at particular high risk for t-AML/MDS.",
author = "S. Yamasaki and R. Suzuki and K. Hatano and K. Fukushima and H. Iida and S. Morishima and Y. Suehiro and T. Fukuda and N. Uchida and H. Uchiyama and H. Ikeda and A. Yokota and K. Tsukasaki and H. Yamaguchi and J. Kuroda and H. Nakamae and Y. Adachi and Ken-ichi Matsuoka and Y. Nakamura and Y. Atsuta and J. Suzumiya",
year = "2017",
month = "7",
day = "1",
doi = "10.1038/bmt.2017.52",
language = "English",
volume = "52",
pages = "969--976",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma

AU - Yamasaki, S.

AU - Suzuki, R.

AU - Hatano, K.

AU - Fukushima, K.

AU - Iida, H.

AU - Morishima, S.

AU - Suehiro, Y.

AU - Fukuda, T.

AU - Uchida, N.

AU - Uchiyama, H.

AU - Ikeda, H.

AU - Yokota, A.

AU - Tsukasaki, K.

AU - Yamaguchi, H.

AU - Kuroda, J.

AU - Nakamae, H.

AU - Adachi, Y.

AU - Matsuoka, Ken-ichi

AU - Nakamura, Y.

AU - Atsuta, Y.

AU - Suzumiya, J.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning remains controversial in patients with relapsed lymphoma. We retrospectively analyzed incidence and risk factors for the development of t-AML/MDS in lymphoma patients treated with autologous or allogeneic HCT. A total of 13 810 lymphoma patients who received autologous (n=9963) or allogeneic (n=3847) HCT between 1985 and 2012 were considered. At a median overall survival (OS) of 52 and 46 months in autologous and allogeneic HCT groups, respectively, lymphoma patients receiving autologous HCT (1.38% at 3 years after autologous HCT) had a significant risk for developing t-AML/MDS compared to allogeneic HCT (0.37% at 3 years after allogeneic HCT, P<0.001). Significant risk factors for the development of t-AML/MDS after autologous and allogeneic HCT were high-stage risk at HCT (P=0.04) or secondary malignancies (P<0.001) and receiving cord blood stem cell (P=0.03) or involved field radiotherapy (P=0.002), respectively. Strategies that carefully select lymphoma patients for autologous HCT, by excluding lymphoma patients with high-stage risk at HCT, may allow the identification of individual lymphoma patients at particular high risk for t-AML/MDS.

AB - Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning remains controversial in patients with relapsed lymphoma. We retrospectively analyzed incidence and risk factors for the development of t-AML/MDS in lymphoma patients treated with autologous or allogeneic HCT. A total of 13 810 lymphoma patients who received autologous (n=9963) or allogeneic (n=3847) HCT between 1985 and 2012 were considered. At a median overall survival (OS) of 52 and 46 months in autologous and allogeneic HCT groups, respectively, lymphoma patients receiving autologous HCT (1.38% at 3 years after autologous HCT) had a significant risk for developing t-AML/MDS compared to allogeneic HCT (0.37% at 3 years after allogeneic HCT, P<0.001). Significant risk factors for the development of t-AML/MDS after autologous and allogeneic HCT were high-stage risk at HCT (P=0.04) or secondary malignancies (P<0.001) and receiving cord blood stem cell (P=0.03) or involved field radiotherapy (P=0.002), respectively. Strategies that carefully select lymphoma patients for autologous HCT, by excluding lymphoma patients with high-stage risk at HCT, may allow the identification of individual lymphoma patients at particular high risk for t-AML/MDS.

UR - http://www.scopus.com/inward/record.url?scp=85016958241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016958241&partnerID=8YFLogxK

U2 - 10.1038/bmt.2017.52

DO - 10.1038/bmt.2017.52

M3 - Article

VL - 52

SP - 969

EP - 976

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -